News & Events

• September 27, 2022
  

  Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation

  C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.

• September 8, 2022
  

  C-Path’s Kristen Swingle Named President

  Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...
• August 26, 2022
  

  Four PKD Reports Published in CJASN

  C-Path and PKDOC are excited to announce that four reports summarizing Sessions 1, 2, and 3B from the 2021 PKD Regulatory Summit have been published in The Clinical Journal of the American Society of Nephrology (CJASN). Please find the associated links below: Drug Development for Cystic Kidney Diseases Perspectives on Drug Development in Autosomal Recessive...
• October 14, 2021
  

  Academic Innovation Leader and Experienced Scientist to Join C-Path’s PKD Consortium

  C-Path today announced it has named Sorin Fedeles, Ph.D., MBA as Executive Director of its Polycystic Kidney Disease Outcomes Consortium (PKDOC), effective October 1, 2021.

• August 21, 2020
  

  C-Path’s PKDOC and The PKD Foundation Set to Collaborate Once Again

  Polycystic Kidney Disease (PKD) is an inherited disorder in which clusters of cysts develop in the kidneys. There are more than 200,000 US cases diagnosed each year and many people with this condition have kidney failure by age 60. To meet the challenge in discovering treatments for PKD, C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) is excited to announce a collaboration with The PKD Foundation, who’s mission is to fund research, advocate for patients and build a community for all impacted by PKD. The agreement renews the significant collaboration between C-Path and The PKD Foundation to facilitate existing and new mutually agreed upon programs to accelerate the pace and reduce the cost of medical product development for the diagnosis and treatment of PKD. Learn more about PKDOC.